People · Operator
Named in public records as an officer, director or promoter · active 2013–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Corvia Medical, Inc. | — | Biotechnology | Series B | $59.9M | $42.1M | 2013 |
David S. Celermajer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David S. Celermajer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul S. LaViolette | 1 | 3 |
| Paul J. LaViolette | 1 | 2 |
| Daniel B. Curtis | 1 | 1 |
| Mark S. Levin | 1 | 1 |
| Gerry S. Brunk | 1 | 1 |
| Hemant S. Taneja | 1 | 1 |
| Uri S. Geiger | 1 | 1 |
| Kevin J. Gillis | 1 | 1 |
| Gerald J. Brunk | 1 | 1 |
| Dan B. Curtis | 1 | 1 |
| David J. Celermajer | 1 | 1 |
| Irit J. Yaniv | 1 | 1 |
| George J. Fazio | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.